Tranexamic Acid (TXA)

Tranexamic Acid

The CRASH-2 2 (Clinical Randomisation of an Anti-fibrinolytic in Significant Haemorrhage 2) study involved the randomisation of over 20,000 patients with, or at risk of significant haemorrhage in 40 countries. The study demonstrated a 32% reduction in death due to haemorrhage, when tranexamic acid is administered within 1 h of injury. The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients, and should be considered for use in practice.

Following the publication of the study, the Trust has been working with Professor Stuart Logan, Director of the Peninsula National Institute of Health Research's Collaboration for Leadership in Applied Health Research and Care to implement the intervention across the South West.

For further information please contact Adrian South, Deputy Director of Clinical Care at adrian.south@swast.nhs.uk

Local Resources

Published Evidence

TXA image

Email this page Print page

News

DEFIB FOR PLYMOUTH'S THEATRE ROYAL FUNDED BY CARDIAC ARREST SURVIVOR
Thanks to the generosity of a cardiac arrest survivor, the Theatre Royal, Plymouth will now have its own defibrillator. Local man Alan Davies collapsed in cardiac arrest while shopping with his wife Glenda in Plymouth city centre back in December 2013. Alan was saved after a member of the public carried out CPR almost immediately after his collapse before an ambulance crew arrived promptly on scene and continued his treatment before he was taken to hospital.
22/07/2016

Rounded corners
Rounded corners
 
© South Western Ambulance Service NHS Foundation Trust 2016 Design by Precedent | Powered by Sitekit